Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Amyloidosis × belantamab mafodotin × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 19 Recurrence 2 Neoplasms, Plasma Cell 1 Immunoglobulin Light-chain Amyloidosis 1 Amyloidosis 1

Interventions

Dexamethasone 5 Lenalidomide 2 Cyclophosphamide 2 Calcium Dobesilate 2 ixazomib 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 carfilzomib 1 belantamab mafodotin 1 auricularum 1 Thalidomide 1 Melphalan 1 Lisaftoclax 1 GTP Cyclohydrolase 1 Drug Evaluation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05145816 2026-02-17

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

University of Texas Southwestern Medical Center

Phase 1/2 Recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡